Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience

Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and s...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, Andrej Borzan, Sven Kurbel
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Subjects:	inflammatory bowel disease vedolizumab treatment outcome
Online Access:	https://www.mdpi.com/1424-8247/16/2/239